Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

2.

A controlled trial of recombinant human erythropoietin after bone marrow transplantation.

Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A, et al.

Blood. 1994 Nov 15;84(10):3327-35.

3.
4.

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.

Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, et al.

J Natl Cancer Inst. 1993 May 19;85(10):801-6.

PMID:
8487324
6.

Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.

Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, Gleason CA, Bifano EM, Millard DD, Davis CB, et al.

Pediatrics. 1995 Jan;95(1):1-8.

PMID:
7770284
8.

Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group.

Biggs JC, Atkinson KA, Booker V, Concannon A, Dart GW, Dodds A, Downs K, Szer J, Turner J, Worthington R.

Bone Marrow Transplant. 1995 Jan;15(1):129-34.

PMID:
7742745
9.

Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation.

Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M, et al.

Br J Haematol. 1994 May;87(1):153-61.

PMID:
7947240
10.

Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy.

Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH.

Cancer. 1999 Oct 1;86(7):1362-7.

PMID:
10506726
11.

A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country.

Avent M, Cory BJ, Galpin J, Ballot DE, Cooper PA, Sherman G, Davies VA.

J Trop Pediatr. 2002 Aug;48(4):227-33.

PMID:
12200985
12.

A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy.

Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI.

Transfusion. 1994 Jan;34(1):66-71.

PMID:
8273133
13.

High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.

Vannucchi AM, Bosi A, Linari S, Guidi S, Longo G, Lombardini L, Mariani MP, Saccardi R, Laszlo D, Rossi Ferrini P.

Haematologica. 1997 Jan-Feb;82(1):53-6.

14.

Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study.

Shannon KM, Mentzer WC, Abels RI, Freeman P, Newton N, Thompson D, Sniderman S, Ballard R, Phibbs RH.

J Pediatr. 1991 Jun;118(6):949-55.

PMID:
2040933
16.

Recombinant human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo-controlled study.

Meyer MP, Meyer JH, Commerford A, Hann FM, Sive AA, Moller G, Jacobs P, Malan AF.

Pediatrics. 1994 Jun;93(6 Pt 1):918-23.

PMID:
8190577
18.

Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.

Klaesson S, Ringdén O, Ljungman P, Lönnqvist B, Wennberg L.

Bone Marrow Transplant. 1994 Apr;13(4):397-402.

PMID:
8019463
19.

Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial.

Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S, Donovan EF, Close NC, Das A.

Pediatrics. 2001 Oct;108(4):934-42.

PMID:
11581447
20.

The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.

Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.

Exp Hematol. 2002 Sep;30(9):1044-50.

PMID:
12225796

Supplemental Content

Support Center